Slavica Bio Chem (HTDS.PK) to Participate in the Moscow International Salon of Inventions and Innovation Technologies "Archimedes-2010"

BELGRADE, Serbia, January 7 - Hard to Treat Diseases (HTDS.PK) (www.htdsmedical.com)
Slavica Bio Chem operating subsidiary (www.slavicabiochem.com ) is
proud to report that IBISS research group is invited, as a representative of
Serbia, to participate in the 13th Moscow International Salon of Inventions
and Innovation Technologies "Archimedes" that is to be held from March 30 to
April 2, 2010 in Moscow, Russia. More information can be found at
eng.archimedes.ru/.

Prof. Dr. Mirjana Stojiljkovic, a Medical Advisor of HTDS, and
a team leader of IBISS research group said, "This invitation came from the
Inventors Association of Serbia, after the competition for the Best
Technological Innovation in Serbia in the year 2009. We are proud that our
innovation "Delay of Glial Scar Formation as a Prerequisite of Recovery after
Central Nervous System Injury" is well recognized, and chosen to represent
Serbian inventors at one of the greatest world contests of Inventions and
Innovation Technologies "Archimedes". Just as a reminder, in the contest for
the Best Technological Innovation in Serbia in the year 2009, Ministry of
Science and Technological Development of Republic of Serbia awarded our
NEUROBIOS team the second place of all scientific projects (and the first
place for biological science) which competed for this prestigious award, for
the establishment of a novel therapeutic approach in reducing and delaying of
glial scar formation, a major factor in the failure of post-injury
neurological recovery after the brain and spinal cord injury.

Prof. Dr. Mirjana Stojiljkovic added: "Last year, the
international jury and commission of experts of the Salon "Archimedes" have
awarded to participants of the exhibition 235 gold and 226 silver medals, 210
diplomas of Rospatent (Federal service on intellectual property, patents and
trade-marks), 250 "Certificates of listeners of the University of inventor"
and 1000 diplomas of gratitude and respect for participation in the
exhibition "Archimedes-2009", and in that way "Archimedes" is one of the
world leading competitions. Salon "Archimedes" allows highlighting and
distributing information about the best achievements of advanced minds of
mankind, gives an additional impulse to development of the market of
intellectual property and attracts new investments into high technology
industries. The contest is organized under the auspices of the Russian
Federation, Moscow City and the World Intellectual Property Organization
(WIPO)."

Additional details and information will be released, via
regular news release or Pink Sheets filing service.

To receive future updates via email, including quarterly newsletters and
company updates that may not be newsworthy, however important to the reader
and followers of the company, please sign up today free at
www.minamargroup.com/updates

Safe Harbor Statement

Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat Diseases, Inc.
that constitute forward-looking statements for purposes of the safe harbor
Provision's under the Private Securities Litigation Reform Act of 1995. The
words or phrases "can be," "expects," "may affect," "believed," "estimate,"
"project," and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to Treat
Diseases, Inc. is not a guarantee of future performance. None of the
information in this filing constitutes or is intended as an offer to sell
securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s
actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important factors, some of
which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those
discussed in Hard to Treat Diseases, Inc.'s press releases, public filings,
and statements by Hard to Treat Diseases, Inc.'s management, including, but
not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of
its existing capital resources, Hard to Treat Diseases, Inc.'s ability to
raise additional capital to fund future operations, HTDS Corporation's
ability to repay its existing indebtedness, the uncertainties involved in
estimating market opportunities and, in identifying contracts which match
Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which such
statements were made. Hard to Treat Diseases, Inc. does not undertake any
obligation to publicly update any forward-looking statement to reflect events
or circumstances after the date on which any such statement is made or to
reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please
contact medicalinfo@htdsmedical.com; For any corporate matters, please
contact www.minamargroup.com/helpdesk , +1-416-597-8884

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo at htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk , +1-416-597-8884